Myriad Genetics Inc
Veridion Score
BETALOW CONF · 6/6 factorsComposite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Why is MYGN moving today?
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
MYGN overview
Related filings and maps
Congress activity in MYGN
No receipt-qualified Congressional disclosure is present for MYGN in the cached public ledger.
MYGN contract awards, year to date.
Public federal awards linked to this ticker.
MYGN lobbying filings, year to date.
Registered lobbying filings matched to Myriad Genetics Inc.
MYRIAD GENETICS, INC.
MYRIAD GENETICS, INC.
TODD STRATEGY GROUP